IMPACT OF ANTI-TNF, VEDOLIZUMAB AND TOFACITINIB ON AORTIC STIFFNESS, CAROTID INTIMA-MEDIA THICKNESS AND CARDIOVASCULAR RISK OF PATIENTS WITH ULCERATIVE COLITIS
Key facts
- Where
- Amiens Cedex 1, FranciaországSee the site
- Phase
- 4. fázis
Where in Franciaország
- Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranciaországToborzás még nem indult
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire Amiens Picardie
- Trial code
- EU 2024-517314-15-00
- Record updated
- 2024. szeptember 10.
- Original description
To compare the CIMT after 3 months of therapy in ulcerative colitis in patients treated by anti-TNF, vedolizumab, and tofacitinibRead full original descriptionShow less
To compare the CIMT after 3 months of therapy in ulcerative colitis in patients treated by anti-TNF, vedolizumab, and tofacitinib
Inclusion: Ulcerative colitis evolving for at least 6 months; Patient older than 18 years; Initiating a treatment by infliximab, adalimumab, golimumab, vedolizumab or tofacitinib; Patient covered by French national health insurance; Written informed consent.
Exclusion: Patients with anti-hypertensive, antiplatelet or lipid-lowering drugs without stable dosage within the 3 months before the study and over the study period; Patients with a cardiovascular event such as myocardial infarction and stroke; Diabetic patient; Pregnant women or breastfeeding; Minor; Patient deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision).